Other languages Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
2.85 ^HKD	-1.04%		+12.20%	-57.08%

Jun. 05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
Jun. 05	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	Jun. 05
Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	Jun. 05
Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting	Jun. 02
Hong Kong Stocks Close Lower Following Mixed Session on Wall Street	May. 29
Alphamab's Phase 3 Trial for Pancreatic Cancer Treatment Fails to Reach Preset Statistical Endpoint; Shares Plunge 38%	May. 28
Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC	May. 28
Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016	May. 21
Alphamab Oncology's 2023 Loss Narrows as Revenue Rises	May. 02
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting	Apr. 09
Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr	Apr. 09
Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting	Apr. 09
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits	Apr. 04
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Suzhou Alphamab Co., Ltd. Announces Renewal of the Lease Agreement	Mar. 28
Alphamab Oncology Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033	Mar. 25
Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine	Mar. 22
Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications	Feb. 06
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	Jan. 24
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24
Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor	Dec. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alphamab Oncology

Equities

9966

KYG0330A1013

Other languages

Filters